trans-Chalcone

Cat. No.: HY-Y0598 Purity: 98.65%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

trans-Chalcone, isolated from Aronia melanocarpa skin, is a biphenolic core structure of flavonoids precursor. trans-Chalcone is a potent fatty acid synthase (FAS) and α-amylase inhibitor. trans-Chalcone causes cellcycle arrest and induces apoptosis in the breastcancer cell line MCF-7. trans-Chalcone has antifungal and anticancer activity.

For research use only. We do not sell to patients.

trans-Chalcone Chemical Structure

CAS No. : 614-47-1

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 44	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 44	In-stock	Estimated Time of Arrival: December 31
Solid
5 g	USD 40	In-stock	Estimated Time of Arrival: December 31
10 g		Get quote
50 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of trans-Chalcone:

Chalcone Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
2008	IC₅₀	33.4 μM Compound: 17	Cytotoxicity in human OV2008 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay Cytotoxicity in human OV2008 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay	[PMID: 28411546]
A2780	IC₅₀	67.5 μM Compound: 17	Cytotoxicity in human A2780 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay Cytotoxicity in human A2780 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay	[PMID: 28411546]
A2780	GI₅₀	7.3 μM Compound: Chalcone	Antiproliferative activity against human A2780 cells assessed as cell growth inhibition measured after 72 hrs by trypan blue assay Antiproliferative activity against human A2780 cells assessed as cell growth inhibition measured after 72 hrs by trypan blue assay	[PMID: 34262643]
A549	IC₅₀	> 10 μM Compound: 69	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 35026948]
A549	IC₅₀	> 20 μM Compound: 1	Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay Inhibition of TNFalpha induced NF-kappaB activation in human A549 cells by luciferase reporter gene assay	[PMID: 19883086]
A549	IC₅₀	69.19 μM Compound: Chalcone	Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay	[PMID: 32992255]
BT-20	IC₅₀	21.1 μM Compound: 17	Cytotoxicity in human BT20 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay Cytotoxicity in human BT20 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay	[PMID: 28411546]
CAL-51	GI₅₀	1.85 μM Compound: SSE14101	Antiproliferative activity against human CAL51 cells assessed as growth inhibition after 3 days by SRB assay Antiproliferative activity against human CAL51 cells assessed as growth inhibition after 3 days by SRB assay	[PMID: 28743509]
CHO	IC₅₀	23 μM Compound: 17	Cytotoxicity in CHO cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay Cytotoxicity in CHO cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay	[PMID: 28411546]
DLD-1	EC₅₀	25 μM Compound: 4	Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay	[PMID: 36356534]
DU-145	IC₅₀	50.1 μM Compound: 17	Cytotoxicity in human DU145 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay Cytotoxicity in human DU145 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay	[PMID: 28411546]
Epithelial cell	IC₅₀	> 50 μM Compound: 1	Cytotoxicity against human kidney epithelial cells after 44 hrs by MTT assay Cytotoxicity against human kidney epithelial cells after 44 hrs by MTT assay	[PMID: 18378360]
FHC	CC₅₀	71 μM Compound: 4	Cytotoxicity against human FHC cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay Cytotoxicity against human FHC cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay	[PMID: 36356534]
HCT-116	EC₅₀	11 μM Compound: 4	Cytotoxicity against p53-/- human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay Cytotoxicity against p53-/- human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay	[PMID: 36356534]
HCT-116	GI₅₀	15.7 μM Compound: 18	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28177228]
HCT-116	GI₅₀	15.7 μM Compound: C1	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26994844]
HCT-116	GI₅₀	3.96 μM Compound: SSE14101	Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 3 days by SRB assay Antiproliferative activity against human HCT116 cells assessed as growth inhibition after 3 days by SRB assay	[PMID: 28743509]
HCT-116	EC₅₀	9.5 μM Compound: 4	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay	[PMID: 36356534]
HEK293	IC₅₀	10.7 μM Compound: 17	Cytotoxicity in HEK293 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay Cytotoxicity in HEK293 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay	[PMID: 28411546]
HEK293	EC₅₀	11 μM Compound: 5d	Inhibition of Wnt3A/beta-catenin signaling in HEK293 cells after 24 hrs by firefly/renilla dual luciferase reporter gene assay Inhibition of Wnt3A/beta-catenin signaling in HEK293 cells after 24 hrs by firefly/renilla dual luciferase reporter gene assay	[PMID: 24275249]
HeLa	EC₅₀	> 50000 nM Compound: 2a	Antimitotic activity in human HeLa cells assessed as cell density loss after 24 hrs by Hoechst 33342 staining Antimitotic activity in human HeLa cells assessed as cell density loss after 24 hrs by Hoechst 33342 staining	[PMID: 23524161]
HepG2	IC₅₀	> 100 μM Compound: 1	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 22658085]
HK-2	IC₅₀	30.5 μM Compound: 1	Growth inhibition of HK2 cells by sulforhodamine assay Growth inhibition of HK2 cells by sulforhodamine assay	[PMID: 17383189]
HL-60	IC₅₀	55.4 μM Compound: 1	Cytotoxicity against human HL60 cells by MTT assay Cytotoxicity against human HL60 cells by MTT assay	[PMID: 25091929]
HT-29	GI₅₀	> 20 μM Compound: Chalcone	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by trypan blue assay Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by trypan blue assay	[PMID: 34262643]
HT-29	EC₅₀	14 μM Compound: 4	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by AlamarBlue-based assay	[PMID: 36356534]
HT-29	IC₅₀	45.9 μM Compound: Chalcone	Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay	[PMID: 32992255]
HT-29	IC₅₀	70 μM Compound: 1	Growth inhibition of HT29 cells by sulforhodamine assay Growth inhibition of HT29 cells by sulforhodamine assay	[PMID: 17383189]
Jurkat	IC₅₀	17.1 μM Compound: 2a	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 23524161]
K562	IC₅₀	3.8 μM Compound: 2ee	Antiproliferative activity against human K562 cells after 5 days by MTT assay Antiproliferative activity against human K562 cells after 5 days by MTT assay	[PMID: 19837593]
KB	IC₅₀	> 10 μM Compound: 69	Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 35026948]
L1210	IC₅₀	> 100 μM Compound: 2a	Cytotoxicity against mouse L1210 cells after 24 hrs by MTT assay Cytotoxicity against mouse L1210 cells after 24 hrs by MTT assay	[PMID: 23524161]
L929	IC₅₀	6.92 μg/mL Compound: 52	Cytotoxicity against mouse L929 cells after 72 hrs by resazurin assay Cytotoxicity against mouse L929 cells after 72 hrs by resazurin assay	[PMID: 22360533]
L929	CC₅₀	89.3 μM Compound: 12	Cytotoxicity in mouse NCTC-929 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in mouse NCTC-929 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31000155]
MCF7	IC₅₀	> 10 μM Compound: 69	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 35026948]
MCF7	GI₅₀	12.4 μM Compound: 18	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28177228]
MCF7	GI₅₀	12.4 μM Compound: C1	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26994844]
MCF7	IC₅₀	12.6 μM Compound: 17	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay	[PMID: 28411546]
MCF7	IC₅₀	63 μM Compound: 1	Growth inhibition of MCF7 cells by sulforhodamine assay Growth inhibition of MCF7 cells by sulforhodamine assay	[PMID: 17383189]
MDA-MB-231	IC₅₀	> 10 μM Compound: 69	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 35026948]
MDA-MB-231	IC₅₀	42.8 μM Compound: Chalcone	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 4 hrs by MTT assay	[PMID: 32992255]
MDA-MB-231	IC₅₀	6.7 μM Compound: 17	Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay	[PMID: 28411546]
MSTO-211H	GI₅₀	8.2 μM Compound: Chalcone	Antiproliferative activity against human MSTO-211H cells assessed as cell growth inhibition measured after 72 hrs by trypan blue assay Antiproliferative activity against human MSTO-211H cells assessed as cell growth inhibition measured after 72 hrs by trypan blue assay	[PMID: 34262643]
NALM-6	IC₅₀	23.9 μM Compound: 1	Cytotoxicity against human NALM6 cells by MTT assay Cytotoxicity against human NALM6 cells by MTT assay	[PMID: 25091929]
Neutrophil	IC₅₀	13 μM Compound: 12	Inhibition of PMA-induce ROS/RNS generation in human neutrophils measured up to 30 mins in presence of 5.5 mM glucose by luminol-amplified chemiluminescence method Inhibition of PMA-induce ROS/RNS generation in human neutrophils measured up to 30 mins in presence of 5.5 mM glucose by luminol-amplified chemiluminescence method	[PMID: 33006891]
Neutrophil	IC₅₀	27 μM Compound: 12	Inhibition of PMA-induce ROS/RNS generation in human neutrophils measured up to 30 mins in presence of 30 mM glucose by luminol-amplified chemiluminescence method Inhibition of PMA-induce ROS/RNS generation in human neutrophils measured up to 30 mins in presence of 30 mM glucose by luminol-amplified chemiluminescence method	[PMID: 33006891]
NIH3T3	IC₅₀	> 20 μM Compound: 1a	Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay Inhibition of cobalt chloride-induced HIF-1 activation expressed in mouse NIH3T3 cells after 8 hrs by luciferase reporter gene assay	[PMID: 21112783]
PANC-1	IC₅₀	26 μM Compound: 17	Cytotoxicity in human PANC1 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay Cytotoxicity in human PANC1 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay	[PMID: 28411546]
PBMC	IC₅₀	27 μM Compound: 2a	Cytotoxicity against human PBMC cells after 24 hrs by MTT assay Cytotoxicity against human PBMC cells after 24 hrs by MTT assay	[PMID: 23524161]
Peritoneal macrophage cell	EC₅₀	9.5 μM Compound: 10	Cytotoxicity against BALB/c mouse peritoneal macrophages incubated for 24 hrs by MTT assay Cytotoxicity against BALB/c mouse peritoneal macrophages incubated for 24 hrs by MTT assay	[PMID: 26055530]
TK-10	IC₅₀	42 μM Compound: 1	Growth inhibition of TK10 cells by sulforhodamine assay Growth inhibition of TK10 cells by sulforhodamine assay	[PMID: 17383189]
WM-115	IC₅₀	43.1 μM Compound: 1	Cytotoxicity against human WM115 cells by MTT assay Cytotoxicity against human WM115 cells by MTT assay	[PMID: 25091929]
ZR-75-1	IC₅₀	13.7 μM Compound: 17	Cytotoxicity in human ZR-75-1 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay Cytotoxicity in human ZR-75-1 cells assessed as reduction in cell viability incubated for 68 hrs by MTT assay	[PMID: 28411546]

In Vitro

trans-Chalcone competitively inhibits porcine pancreatic α-amylase with a K_i of 48 μM^[2].
trans-Chalcone (30.23-98.03 μM; 24 hours) induces cell cycle arrest and apoptosis in MCF-7 cells^[1].
trans-Chalcone (20-80 μM; 24, 48 hours) reduces the expression of the apoptosis-related protein Bcl-2^[1].
trans-Chalcone (58.25 μM; 6, 24 hours) has greater inhibition of Bcl-2, induction of APAF1 and BAX, and strong induction of CIDEA in 24 hours^[1].
trans-Chalcone (24 hours) inhibits MCF-7 cell viability (IC₂₀=30.23 μM; IC₅₀=58.25 μM; IC₈₀=98.03 μM). trans-Chalcone (48 h) has IC₅₀s of 41.53 μM and 48.41 μM for MCF-7 and 3T3 cell lines, respectively. trans-Chalcone exhibits a pronounced cytotoxicity activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	MCF-7 cell
Concentration:	30.23, 58.25, 98.03 μM
Incubation Time:	24 hours
Result:	Induced apoptosis of the breast cancer cell line.

Cell Cycle Analysis^[1]

Cell Line:	MCF-7 cell
Concentration:	30.23, 58.25, 98.03 μM
Incubation Time:	24 hours
Result:	Caused cell cycle arrest in G1.

Western Blot Analysis^[1]

Cell Line:	MCF-7 cell
Concentration:	20, 40, 80 μM
Incubation Time:	24, 48 hours
Result:	Reduced the expression of the apoptosis-related protein Bcl-2 and induced the expression of the CIDEA gene. There was marked degradation of cyclin D1 at 48 h.

RT-PCR^[1]

Cell Line:	MCF-7 cell
Concentration:	58.25 μM
Incubation Time:	6, 24 hours
Result:	Had greater inhibition of Bcl-2, induction of APAF1 and BAX, and strong induction of CIDEA in 24 hours.

Molecular Weight

208.26

Formula

C₁₅H₁₂O

CAS No.

614-47-1

Appearance

Solid

Color

Off-white to light yellow

SMILES

O=C(C1=CC=CC=C1)/C=C/C2=CC=CC=C2

Structure Classification

Flavonoids

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (480.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.8017 mL	24.0085 mL	48.0169 mL
5 mM	0.9603 mL	4.8017 mL	9.6034 mL
10 mM	0.4802 mL	2.4008 mL	4.8017 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (12.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (12.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (12.00 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.65%

Select Batch:

Data Sheet (278 KB) SDS (393 KB)

COA (248 KB) HNMR (120 KB) RP-HPLC (252 KB)

Handling Instructions (2659 KB)

References

[1]. Luis Felipe Buso Bortolotto, et al. Cytotoxicity of trans-chalcone and licochalcone A against breast cancer cells is due to apoptosis induction and cell cycle arrest. Biomed Pharmacother. 2017 Jan;85:425-433. [Content Brief]

[2]. Mahmoud Najafian, et al. Trans-chalcone: a novel small molecule inhibitor of mammalian alpha-amylase. Mol Biol Rep. 2011 Mar;38(3):1617-20. [Content Brief]

[3]. Tamires Aparecida Bitencourt, et al. Trans-chalcone and quercetin down-regulate fatty acid synthase gene expression and reduce ergosterol content in the human pathogenic dermatophyte Trichophyton rubrum. BMC Complement Altern Med. 2013 Sep 17;13:229. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.8017 mL	24.0085 mL	48.0169 mL	120.0423 mL
	5 mM	0.9603 mL	4.8017 mL	9.6034 mL	24.0085 mL
	10 mM	0.4802 mL	2.4008 mL	4.8017 mL	12.0042 mL
	15 mM	0.3201 mL	1.6006 mL	3.2011 mL	8.0028 mL
	20 mM	0.2401 mL	1.2004 mL	2.4008 mL	6.0021 mL
	25 mM	0.1921 mL	0.9603 mL	1.9207 mL	4.8017 mL
	30 mM	0.1601 mL	0.8003 mL	1.6006 mL	4.0014 mL
	40 mM	0.1200 mL	0.6002 mL	1.2004 mL	3.0011 mL
	50 mM	0.0960 mL	0.4802 mL	0.9603 mL	2.4008 mL
	60 mM	0.0800 mL	0.4001 mL	0.8003 mL	2.0007 mL
	80 mM	0.0600 mL	0.3001 mL	0.6002 mL	1.5005 mL
	100 mM	0.0480 mL	0.2401 mL	0.4802 mL	1.2004 mL

trans-Chalcone Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

trans-Chalcone614-47-1Fatty Acid Synthase (FASN)ApoptosisFungalα-amylasecyclearrestbreastcancerMCF-7Bcl-2CIDEAAPAF1BAXInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

trans-Chalcone

Other Forms of trans-Chalcone:

trans-Chalcone Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

trans-Chalcone Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

trans-Chalcone Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report